- Home
- IAF vs MCRB Comparison
IAF vs MCRB Comparison
Compare IAF & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAF
- MCRB
- Stock Information
- Founded
- IAF 1985
- MCRB 2010
- Country
- IAF United States
- MCRB United States
- Employees
- IAF N/A
- MCRB N/A
- Industry
- IAF Finance/Investors Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- IAF Finance
- MCRB Health Care
- Exchange
- IAF Nasdaq
- MCRB Nasdaq
- Market Cap
- IAF 123.6M
- MCRB 103.7M
- IPO Year
- IAF N/A
- MCRB 2015
- Fundamental
- Price
- IAF $4.46
- MCRB $14.53
- Analyst Decision
- IAF
- MCRB Hold
- Analyst Count
- IAF 0
- MCRB 4
- Target Price
- IAF N/A
- MCRB $73.67
- AVG Volume (30 Days)
- IAF 90.4K
- MCRB 164.6K
- Earning Date
- IAF 01-01-0001
- MCRB 08-06-2025
- Dividend Yield
- IAF 11.44%
- MCRB N/A
- EPS Growth
- IAF N/A
- MCRB N/A
- EPS
- IAF N/A
- MCRB 8.98
- Revenue
- IAF N/A
- MCRB N/A
- Revenue This Year
- IAF N/A
- MCRB N/A
- Revenue Next Year
- IAF N/A
- MCRB N/A
- P/E Ratio
- IAF N/A
- MCRB $1.74
- Revenue Growth
- IAF N/A
- MCRB N/A
- 52 Week Low
- IAF $3.60
- MCRB $6.53
- 52 Week High
- IAF $4.59
- MCRB $29.40
- Technical
- Relative Strength Index (RSI)
- IAF 49.66
- MCRB 66.40
- Support Level
- IAF $4.47
- MCRB $11.15
- Resistance Level
- IAF $4.54
- MCRB $14.78
- Average True Range (ATR)
- IAF 0.05
- MCRB 1.38
- MACD
- IAF -0.01
- MCRB -0.05
- Stochastic Oscillator
- IAF 33.33
- MCRB 72.33
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.